Logo image of FULC

FULCRUM THERAPEUTICS INC (FULC) Stock Fundamental Analysis

NASDAQ:FULC - Nasdaq - US3596161097 - Common Stock - Currency: USD

3.85  0 (0%)

After market: 3.85 0 (0%)

Fundamental Rating

3

FULC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. FULC has a great financial health rating, but its profitability evaluates not so good. FULC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year FULC has reported negative net income.
In the past year FULC has reported a negative cash flow from operations.
In the past 5 years FULC always reported negative net income.
FULC had a negative operating cash flow in each of the past 5 years.
FULC Yearly Net Income VS EBIT VS OCF VS FCFFULC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

FULC has a Return On Assets of -6.42%. This is in the better half of the industry: FULC outperforms 75.14% of its industry peers.
With a decent Return On Equity value of -6.96%, FULC is doing good in the industry, outperforming 79.46% of the companies in the same industry.
Industry RankSector Rank
ROA -6.42%
ROE -6.96%
ROIC N/A
ROA(3y)-40.21%
ROA(5y)-51.33%
ROE(3y)-44.95%
ROE(5y)-62.45%
ROIC(3y)N/A
ROIC(5y)N/A
FULC Yearly ROA, ROE, ROICFULC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FULC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FULC Yearly Profit, Operating, Gross MarginsFULC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

8

2. Health

2.1 Basic Checks

FULC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FULC has been increased compared to 1 year ago.
The number of shares outstanding for FULC has been increased compared to 5 years ago.
There is no outstanding debt for FULC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FULC Yearly Shares OutstandingFULC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
FULC Yearly Total Debt VS Total AssetsFULC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 4.26 indicates that FULC is not in any danger for bankruptcy at the moment.
The Altman-Z score of FULC (4.26) is better than 78.92% of its industry peers.
FULC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.26
ROIC/WACCN/A
WACC9.77%
FULC Yearly LT Debt VS Equity VS FCFFULC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 18.44 indicates that FULC has no problem at all paying its short term obligations.
The Current ratio of FULC (18.44) is better than 90.81% of its industry peers.
A Quick Ratio of 18.44 indicates that FULC has no problem at all paying its short term obligations.
FULC's Quick ratio of 18.44 is amongst the best of the industry. FULC outperforms 90.81% of its industry peers.
Industry RankSector Rank
Current Ratio 18.44
Quick Ratio 18.44
FULC Yearly Current Assets VS Current LiabilitesFULC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 81.55% over the past year.
The Revenue has grown by 2974.94% in the past year. This is a very strong growth!
Measured over the past years, FULC shows a very negative growth in Revenue. The Revenue has been decreasing by -31.74% on average per year.
EPS 1Y (TTM)81.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.26%
Revenue 1Y (TTM)2974.94%
Revenue growth 3Y-31.74%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

FULC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.49% yearly.
FULC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.96% yearly.
EPS Next Y85.47%
EPS Next 2Y7.48%
EPS Next 3Y-2.04%
EPS Next 5Y7.49%
Revenue Next Year3367.74%
Revenue Next 2Y-41.42%
Revenue Next 3Y113.54%
Revenue Next 5Y15.96%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FULC Yearly Revenue VS EstimatesFULC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
FULC Yearly EPS VS EstimatesFULC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FULC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FULC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FULC Price Earnings VS Forward Price EarningsFULC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FULC Per share dataFULC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A cheap valuation may be justified as FULC's earnings are expected to decrease with -2.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.48%
EPS Next 3Y-2.04%

More info and screens

0

5. Dividend

5.1 Amount

FULC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FULCRUM THERAPEUTICS INC

NASDAQ:FULC (2/21/2025, 8:22:30 PM)

After market: 3.85 0 (0%)

3.85

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)02-25 2025-02-25/bmo
Inst Owners96.31%
Inst Owner Change-6.77%
Ins Owners0.68%
Ins Owner Change0%
Market Cap207.67M
Analysts73.85
Price Target5.78 (50.13%)
Short Float %8.19%
Short Ratio5.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3469.46%
Min EPS beat(2)15.39%
Max EPS beat(2)6923.53%
EPS beat(4)4
Avg EPS beat(4)1737.61%
Min EPS beat(4)3.64%
Max EPS beat(4)6923.53%
EPS beat(8)7
Avg EPS beat(8)873.81%
EPS beat(12)9
Avg EPS beat(12)583.94%
EPS beat(16)13
Avg EPS beat(16)441.22%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.21%
PT rev (3m)7.21%
EPS NQ rev (1m)-2.22%
EPS NQ rev (3m)28.97%
EPS NY rev (1m)-3.62%
EPS NY rev (3m)19.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)0.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.57
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 0.81
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)-1.33
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS1.5
BVpS4.77
TBVpS4.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.42%
ROE -6.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.21%
ROA(5y)-51.33%
ROE(3y)-44.95%
ROE(5y)-62.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.2%
Cap/Sales 0.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.44
Quick Ratio 18.44
Altman-Z 4.26
F-Score5
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)57.52%
Cap/Depr(5y)54.07%
Cap/Sales(3y)19.32%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.26%
EPS Next Y85.47%
EPS Next 2Y7.48%
EPS Next 3Y-2.04%
EPS Next 5Y7.49%
Revenue 1Y (TTM)2974.94%
Revenue growth 3Y-31.74%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year3367.74%
Revenue Next 2Y-41.42%
Revenue Next 3Y113.54%
Revenue Next 5Y15.96%
EBIT growth 1Y74.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year84.91%
EBIT Next 3Y12.61%
EBIT Next 5YN/A
FCF growth 1Y91.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y91.32%
OCF growth 3YN/A
OCF growth 5YN/A